Introduction: Heart failure with reduced ejection fraction (HFrEF) is associated with a worse
outcome. Heart rate (HR) is related to outcome in HFrEF. Ivabradine selectively inhibits If …

Objectives To assess the beneficial and harmful effects of adding ivabradine to usual care in
participants with heart failure. Design A systematic review with meta-analysis and trial …

Aims The SHIFT trial showed that ivabradine reduced heart rate (HR) and the risk of
cardiovascular outcomes. Concerns remain over the efficacy and safety of ivabradine on …

Intravenous inotropic therapy can be used in patients with advanced heart failure, as
palliative therapy or as a bridge to cardiac transplantation or mechanical circulatory support …

Background Ivabradine is a heart rate-lowering drug that selectively inhibits the funny (If)
current of the sinoatrial node. It is currently recommended in patients with heart failure (HF) …

Background Initiating ivabradine in acute heart failure (HF) is still controversial. Hypothesis
Ivabradine might be effective to be added in acute but hemodynamically stable HF. Methods …

Background: Advanced heart failure (HF) is a progressive disease with high mortality and
limited medical therapeutic options. Long-term mechanical circulatory support and heart …

Ivabradine is an established treatment for chronic heart failure with reduced ejection fraction
(HFrEF); however, it is not used for acute heart failure treatment. Negative inotropic effects …

Background: Heart failure is a chronic disease linked with significant morbidity and mortality,
and uncontrolled resting heart rate is a risk factor for adverse outcomes. This systematic …

Introduction The efficacy and safety of Ivabradine for patients with acute heart failure (AHF)
is controversial, and there are few clinical trials addressing this topic. Methods We …